The immunological basis of psoriasis

    Research output: Contribution to journalArticlepeer-review


    Evidence that psoriasis is an immune-mediated disorder comes from laboratory studies, clinical observation, and use of targeted therapies. Immunohistochemical studies have shown that the majority of T cells in psoriatic plaques are CD45RO+ memory-effector T cells that migrate into skin in recognition of an as yet undetermined antigen. There is also a predominance of Th1 cytokines, namely interferon gamma, in psoriatic plaques, in contrast to the predominance of Th2 cytokines found in atopic: dermatitis. The efficacy of therapeutic agents that target T cells, such as anti-CD4+ monoclonal antibodies, cyclosporin, and interleukin-2 fusion toxin, has provided further substantial evidence that psoriasis is a T-cell-mediated disease. New T-cell targeted approaches and cytokine modulation are advancing basic science in providing an understanding of the evidence for the importance of the immune process in the biology of psoriasis.
    Original languageEnglish
    Pages (from-to)1-5
    Number of pages4
    JournalJournal of the European Academy of Dermatology and Venereology
    Issue number2
    Publication statusPublished - Jul 2003


    • Anti-CD4+ monoclonal antibodies
    • Atopic dermatitis
    • CD45RO+ T cells
    • Cyclosporin
    • IL-2 fusion toxin
    • Psoriasis
    • T-cell subsets
    • Th1/Th2 cytokines


    Dive into the research topics of 'The immunological basis of psoriasis'. Together they form a unique fingerprint.

    Cite this